Company intelligence / Profile preview
Sinovent
Suzhou, Jiangsu, Chinasinovent.com.cn ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Sinovent has established a pipeline of innovative drug candidates leveraging proprietary technology platforms in targeted therapies, anti-infectives, and next-generation ADCs. Their most advanced programs include a CLDN18.2-targeted therapy currently in Phase I/II clinical trials for gastroesophageal junction adenocarcinoma and other solid tumors. The company also has licensing agreements with Everest Medicines and SinoMab to develop novel BTK inhibitors for renal diseases globally.
- Therapeutic areas
- OncologyEndocrinologyImmunologyCardiovascularInfectious Diseases
- Modalities
- Small moleculesAntibody-drug conjugates (ADCs)PROTACs (Proteolysis Targeting Chimeras)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Everest MedicinesSinoMab
Beyond the preview
Go deeper on Sinovent.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinovent.